ABSTRACT Background. Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine neoplasm with propensity for lymphatic spread. The rarity of MCC has limited analysis of factors associated with a positive sentinel lymph node biopsy (SLNB) and survival. Methods. Review of a prospective MCC database was performed. Factors associated with SLNB positivity were analyzed. Univariate and multivariate analyses of factors associated with recurrence and survival were performed using the cumulative incidence (CI) function, treating death from other causes as a competing risk. Results. From 1996 to 2010, a total of 153 patients with localized MCC underwent SLNB, of whom 45 (29%) were positive. Factors associated with SLNB positivity were primary tumor size (25% B2 cm vs. 45% [2 cm; P = 0.02) and presence of lymphovascular invasion (LVI) (55% LVI positive vs. 4% LVI negative; P \ 0.01). SLNBpositive patients were more likely to receive radiation or chemotherapy (60% vs. 7%, P \ 0.01). With median follow-up of 41 months, there were 16 nodal/distant recurrences (10%), 11 deaths from MCC (7%), and 27 death from other causes (18%). The 2-year CIs of recurrence or death from MCC were 12% and 6%, respectively. There was no difference in recurrence or death from MCC between SLNB-positive and -negative patients. The 2-year CIs of recurrence or death from MCC for LVI-positive patients were 30% and 15%, respectively. No LVI-negative patient experienced recurrence of disease or died of MCC. Discussion. SLNB identifies occult nodal metastases in 29% of patients with localized MCC. Predictors of SLNB positivity are tumor size and presence of lymphovascular invasion (LVI). Patients with SLNB-positive disease are more likely to receive further treatment; however, sentinel lymph node (SLN) status is not associated with recurrence or survival. In contrast, LVI is strongly associated with both recurrence and survival.
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Originally described as trabecular carcinoma, Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine neoplasm with an incidence of \0.50 per 100,000 personyears. [1] [2] [3] [4] [5] [6] The natural history of MCC remains poorly characterized and is based on small case series limited by incomplete staging, heterogeneous treatment, short followup, and missing recurrence information. 4, [7] [8] [9] [10] [11] [12] Large database series, such as those utilizing the Surveillance, Epidemiology and End Results (SEER) Program, the National Cancer Data Base (NCDB), and governmental cancer registries, have attempted to overcome these limitations, but are constrained by the limited information captured. [13] [14] [15] For example, neither the SEER program nor the NCDB record disease-specific survival, recurrence patterns, or completely characterize adjuvant therapy.
MCC has a propensity for lymphatic spread: 24-31% of patients present with clinically evident nodal disease, and a similar proportion of the clinically node-negative patients harbor micrometastatic disease. 13, 14, 16 Sentinel lymph node biopsy (SLNB) is a strong predictor of outcome and an established technique to stage the draining nodal basin in breast cancer and melanoma. 17, 18 The use of SLNB in MCC has been described in an effort to identify patients who might benefit from additional treatment. 10, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] However, the small numbers of cases in individual series and lack of detailed staging, recurrence, and follow-up information in the larger database studies have limited a rigorous evaluation of the SLNB procedure in MCC.
Here, we present our experience in patients with localized MCC who underwent SLNB. We describe pretreatment and pathologic variables associated with SLNB positivity. Further, we detail subsequent treatment after SLNB (completion lymph node dissection [CLND], radiotherapy [RT] , and/or chemotherapy) and compare the recurrence and survival between SLNB-positive and -negative patients.
PATIENTS AND METHODS

Patients Selection and Pretreatment Evaluation
Patients with histologically confirmed MCC and no evidence of either clinically involved lymph nodes or metastatic disease (stage I or II, American Joint Commission on Cancer [AJCC] 7th edition) who underwent SLNB were identified from a prospective database at Memorial Sloan-Kettering Cancer Center (MSKCC). 14, 29 The MSKCC Institutional Review Board approved the study design.
SLNB Procedure and Examination of SLN
Patients underwent excision of their primary tumor and SLNB as previously described. 23, 24 Briefly, a combination of technetium 99 m ( 99 Tc)-radiolabeled sulfur colloid injected preoperatively and Lymphazurin blue injected intraoperatively at the site of the tumor were used for SLN identification.
SLNB specimens were analyzed as previously described. 23 Briefly, specimens were processed for hematoxylin and eosin (H&E). One initial level per lymph node was stained for H&E and examined. If metastatic MCC was identified, no further studies were performed. If no tumor was found, three additional sections were taken from the tissue block. The first and last were stained for H&E. The section in between was analyzed via immunohistochemistry (IHC) as previously described. 23 If the primary tumor was known to be positive for CK20, Cam5.2, or chromogranin, the stronger of those markers was used. If the immunophenotype of the primary tumor was unknown, additional sections were taken and IHC was performed using all of the aforementioned markers.
Subsequent Treatment, Follow-up, and Recurrence
After SLNB, treatment decisions were made at the discretion of treating physician(s). RT is defined as C50 Gy to the draining nodal basin of the primary tumor for 5 days a week over a 5-6-week course performed within 8 weeks of surgery. Chemotherapy consisted of cisplatin or carboplatin with etoposide for 4-6 cycles over 8-12 weeks and was initiated within 8 weeks of surgery, or after RT (when given). In follow-up, patients were seen every 2-3 months for 1 year and every 6-12 months thereafter. Follow-up consisted of a complete skin/lymph node evaluation, with laboratory and imaging studies obtained as clinically indicated. Recurrence was defined as any patient, physician, or radiographically discovered evidence of nodal or distant tumor. Local or in-transit recurrences were not included as a variable in this analysis, as SLNB status would not be predicted to impact local or in-transit recurrence. Date of first recurrence was defined as the first notation in the medical record indicating the nodal or distant recurrence. Vital status and cause of death were obtained for every patient from the medical record, direct patient/family contact, and correspondence with referring physicians.
Statistical Analysis
Statistical analysis was performed by SAS, version 9.1 (SAS Institute, Cary, NC) and R software, version 2.1 (http://www.r-project.org). Fisher's exact test was used to examine covariate differences based on SLN status. The cumulative incidence (CI) function was used to estimate the probabilities of time from treatment to nodal/distant recurrence or death due to MCC. Patients with MCC who died of other causes or died without nodal/distant recurrences were treated as competing events for analysis of survival and recurrence, respectively. 30, 31 Gray's test was used to determine differences in CI outcomes between groups. 32 
RESULTS
Patient Characteristics
One hundred fifty-three patients presented with clinically localized MCC and underwent SLNB from 1996 to 2010. Seven of these patients had their SLNB procedure done before presenting at MSKCC and had complete pretreatment and SLNB procedure information available for review. They are included in the analysis of factors associated with SLNB positivity, but excluded from the recurrence and survival analysis to prevent bias as a result of their presentation status after SLNB with a recurrence.
Differences in Patient, Tumor, and Treatment Characteristics between SLNB-Positive and -Negative Patients
There were 45 patients (29%) with SLNB-positive disease. Table 1 summarizes differences in pretreatment characteristics on the basis of SLN status. Patients with SLNB-positive disease had larger primary tumors (14 vs. 12 mm; P = 0.03); thus, size (defined by clinical stage 1 vs. 2) was a predictor of SLNB positivity (25% B2 cm vs. 48% [2 cm; P \ 0.01). Notably, of the 66 patients with primary tumors B1 cm in maximal diameter who underwent SLNB, there were 17 (26%) with SLNB-positive disease (Fig. 1a) . Table 2 Figure 2 details the treatment profile of all patients after SLNB. SLNB-positive patients were more likely to undergo CLND (47% vs. \ 2%, P \ 0.01) and were more likely to receive post-SLNB nodal RT (either as adjuvant RT after CLND or as therapeutic RT after a finding of SLNB positivity) and/or chemotherapy (60% vs. 6%, P \ 0.01). Of the 108 patients with SLNB negativity, 99 (92%) underwent no further treatment, 2 (2%) underwent CLND, and 7 (6%) underwent nodal RT.
Nodal or Distant Recurrence and Death from MCC
Median follow-up was 41 months. Figure 2 describes the patterns of recurrence for each treatment group. There were two local recurrences (one SLNB positive and one SLNB negative) and six in-transit recurrences (four SLNB positive, two SLNB negative) that are not included in further analysis (see methods). Overall, there were ten nodal (7%) and nine distant (6%) recurrences. In the 45 Figure 3 shows the CIs of recurrence (top) and death from MCC (bottom). Sixteen patients developed recurrence and 25 patients died without a recurrence (Fig. 3, top) . Eleven patients died of MCC and 27 died of other causes (Fig. 3, bottom) . Greater than 90% of all recurrences and deaths from MCC occurred within 2 and 5 years of followup, respectively. Figure 4 summarizes the CIs of recurrence and death from MCC, subdivided by SLNB status, clinical stage, and LVI. The 2-year CI of recurrence was 12% for all patients. There was no difference in the CI of recurrence on the basis of SLNB status (Fig. 4 , top left, P = 0.86) and there was an insignificant trend toward increased recurrence based on primary tumor size (Fig. 4 , middle left; P = 0.26). However, there was a significant difference in the CI of recurrence based on LVI status of the primary tumor (Fig. 3, bottom left) . Notably, no LVI-negative patient developed recurrence during follow-up, while the 2-year CI of nodal/distant recurrence in the LVI-positive patients was 30% (P \ 0.01).
The 2-year CI of death from MCC was 6%. There was no difference in the CI of death from MCC on the basis of SLN status (Fig. 4 , top right; P = 0.89). There was a borderline significant probability of death from MCC on the basis of primary tumor size (Fig. 4 , middle right; P = 0.05). There was a significant difference between the 2-year CI of death from MCC on the basis of LVI of the primary tumor (Fig. 4, bottom right) . Notably, no LVInegative patient died from MCC during follow-up, while the 2-year CI of death from MCC in LVI-positive patients was 15% (P \ 0.01).
Among 83 patients with follow up of C3 years, there were seven recurrences (8.4%; five nodal, two distant). No recurrence occurred after 3 years. There were three deaths from MCC (3.6%) and 21 deaths from other causes (25%). All deaths from MCC occurred after 3 years.
DISCUSSION
To our knowledge, this is the largest description of the SLNB procedure in MCC. We found a 29% rate of SLNB positivity in patients presenting with localized MCC. This is consistent with other reports in the literature, which cite SLNB-positive rates of 19-38%. [8] [9] [10] 16, 21, 23, 24, [26] [27] [28] Primary tumor size and LVI in the primary tumor were associated with SLNB positivity. This is consistent with a previous report from our institution and a recent series from the University of Michigan where larger primary tumors were more likely to have nodal micrometastases. 16, 28 However, we could not define a size of primary tumor for which the probability of a positive SLN was insignificant: 26% of patients with primary tumors of B1 cm were SLNB positive. This is in contrast to Stokes' review of the Department of Veterans Affairs database in which only 4% of patients with tumors of B1 cm were SLNB positive. 9 Our results are more consistent with other single institution series where the rate of SLN positivity in tumors of B1 cm ranges 15-42%. 8, 21, 28, 33, 34 Not unexpectedly, we found that SLNB-positive patients were more likely to receive further treatment, in the form of CLND (47%), nodal RT (31%), systemic chemotherapy (9%), or chemotherapy and nodal RT (20%). Importantly, with [ 3 years of median follow-up, recurrence and death from MCC were low (12% and 6%, respectively, at 2 years), highlighting the ability to achieve disease control in clinically node-negative MCC. Among the 21 SLNB-positive patients who received a CLND ± adjuvant nodal RT and the 17 SLNB-positive patients who received therapeutic nodal RT (without CLND), there was only one nodal recurrence, occurring in a patient who was treated with a CLND alone. These observations suggest that therapeutic RT may be at least as effective as CLND for nodal basin control after a finding of SLNB positivity. Treatment decisions should take into account side-effects and patient factors/preferences. Further, 71% of patients with SLNB positivity received no adjuvant systemic chemotherapy, and only 6% developed a distant recurrence. With such a low distant recurrence rate without further treatment, it is unlikely that the addition of unproven adjuvant systemic chemotherapy after a finding of SLNB positivity will be shown to benefit this patient population.
In patients with SLNB negativity, 92% received no further treatment, of whom 13% developed nodal or distant recurrence. Importantly, we found an 8% incidence of nodal recurrence after SLNB negativity, with no further treatment, corresponding to a 15% false-negative rate. To our knowledge, this is the first report of the clinical nodal failure rate and false-negative rate of the SLNB procedure in MCC. This is rate is remarkably similar to the 18% and 10% false-negative rates for the SLNB procedure in melanoma and breast cancer, respectively. 18, 35 We found additional positive non-SLN in 29% of patients (6 of 21) who underwent CLND after a finding of SLNB positivity, which is lower than the 50% rate of positive non-SLN reported in other series. 8, 20 However, each of these series had only 8 SLNB-positive patients who underwent CLND. Only 1 of 6 patients with positive non-SLN in our series developed recurrence (distant).
SLN status was not associated with recurrence or death from MCC. These results are in contrast to other reports of differences in recurrence and survival that are based on SLN status. Gupta reported on the Dana-Farber experience and performed a meta-analysis of reported series of patients undergoing SLNB for MCC, identifying a total of 122 cases. 21 He found a 60% 3-year recurrence rate for SLNB-positive patients compared to 20% for SLNB-negative patients (P = 0.03). Similarly, Mehrany et al. performed a meta-analysis of patients undergoing SLNB for MCC, identifying a total of 60 cases. 26 They found a 33% 1-year recurrence rate for SLNB-positive patients, compared to 3% for SLNB-negative patients (P = 0.005). However, as discussed above and delineated by others, relying on large databases and meta-analyses to characterize MCC is misleading. 34 For example, several of the studies included in the above meta-analyses included local recurrence as an outcome measure. However, we would argue that local recurrence is not a relevant outcome when discussing the prognostic role of SLNB. Furthermore, SLN status was not associated with recurrence in our series, even when local and in-transit recurrences were included (analysis not shown). In their analysis of 5,823 patients with MCC from the NCDB, Lemos et al. found that patients with pathologically proven negative lymph node (i.e., SLNB negativity) had improved 5-year overall survival compared those who did not undergo the SLNB procedure (76% vs. 59%, P \ 0.0001).
14 This report formed the basis for the most current AJCC staging system, which separates stage I and II into (a) and (b) subgroups, where (a) denotes a negative pathologic node evaluation, generally by SLNB. 29 However, because the NCDB database does not record recurrence or cause of death, it is impossible to assess the direct impact of SLN status on Merkel cell-specific outcome in this elderly population, where death from other causes is so common. The lack of association between SLN status and outcome is puzzling. Unlike breast cancer and melanoma, pathologic nodal status in patients with clinically negative nodes is not predictive of outcome in MCC, yet patients with clinically apparent nodal metastases have substantial disease-specific mortality. One hypothesis is that treatment for microscopically positive nodal disease in MCC is so effective that it interrupts the progression to systemic spread. This observation is in contrast to both melanoma and breast cancer, where SLN-positive patients also receive more treatment, yet SLN status remains a strong independent predictor of outcome. Alternatively, in patients with clinically negative nodes, prognosis may be driven by more powerful histologic features of the primary tumor, such as LVI. Although our current report is the largest to describe the SLNB procedure in MCC, selection bias in subsequent treatment decisions makes a causal relationship between SLNB status and outcome impossible. Currently, we offer SLNB to all patients with invasive MCC.
In contrast to SLN status, we found that LVI in the primary tumor was highly associated with recurrence and death from MCC. In fact, there were no recurrences or deaths from MCC in patients without LVI. The presence of LVI was also highly predictive of SLNB positivity, which consistent with our previous report of the association between histologic features of the primary tumor (depth of invasion, LVI, and tumor growth pattern) and SLNB positivity and outcomes, but in contrast to the findings of Schwartz from the University of Michigan where depth and growth pattern, but not LVI, were associated with SLNB positivity. 28, 36 In the present report, only 4% of patients with LVI negativity had SLNB positivity, compared to 55% in those patients with LVI positivity. However, the 95% confidence intervals for the 4% rate of SLNB positivity in patients without LVI is 2-14%. Thus, although the predicted rate of SLNB positivity in LVI-negative patients is near the threshold for which SLNB is generally not recommended for patients with melanoma, observations of many more patients are clearly required before any recommendation can be made on the use of SLNB solely on the basis of LVI status or other histologic parameters of the primary tumor.
In summary, SLNB is positive in 29% of patients with clinically node-negative MCC. Patients with larger primary tumors are more likely to have SLNB positivity; however, there is a high rate of SLNB positivity in small (B1 cm) tumors. Less than 5% of patients with LVI negativity of their primary tumor had SLNB positivity. The false-negative rate of the SLNB procedure in MCC is 15%. Patients with SLNB positivity are more likely to receive further treatment, but SLN status is not associated with increased recurrence or death from MCC. In contrast, LVI in the primary tumor is strongly associated with recurrence and death from MCC. Thus, LVI may be more informative than SLNB status in predicting outcomes in MCC. The low rates of recurrence and death from MCC in patients with SLNB positivity argues against the use of adjuvant systemic chemotherapy. Inclusion of LVI into subsequent staging and treatment algorithms may allow for both improved definition of what subset of patients with MCC should undergo SLNB and, of the patients that undergo SLNB, what subset should undergo further treatment for clinically localized MCC.
In conclusion, this analysis highlights the importance of accurate, complete, and detailed natural history observations in rare diseases (where prospective randomized trials are neither available nor practical) to guide staging, treatment, and follow-up recommendations.
